This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial

Saturday, September 14, 2019

Submitted by


Jonathan G. Howlett, Amanda Stebbins, Mark C. Petrie, Pardeep S. Jhund, Serenella Castelvecchio, Alexander Cherniavsky, Carla A. Sueta, Ambuj Roy, Ileana L. Piña, Raphael Wurm, Mark H. Drazner, Bert Andersson, Carmen Batlle, Michele Senni, Lukasz Chrzanowski, Bela Merkely, Peter Carson, Patrice M. Desvigne-Nickens, Kerry L. Lee, Eric J. Velazquez, Hussein R. Al-Khalidi on behalf of the STICH Trial Investigators

This study reports ten year outcomes of the STICH trial. Comparing CABG to medical therapy groups, the authors note that CABG reduced all cause, cardiovascular, and heart failure hospitalizations. This included time-to-first and recurrent events. This was due to fewer total cardiovascular hospitalizations, the majority due to heart failure.


Add comment

Log in or register to post comments